NRSNW (NeuroSense Therapeutics) Moat Score: 2/10 (As of Jun. 25, 2026)


NRSNW NeuroSense Therapeutics Ltd NRSNW
29 GF Score
Price $0.21
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Moat Score?

NeuroSense Therapeutics NRSNW 29 Moat Score is 2 as of Jun. 25, 2026. GuruFocus rates NRSNW with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,405 Biotechnology companies, NeuroSense Therapeutics ranks better than 58.15% on this metric.

NeuroSense Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

NeuroSense Therapeutics has No Moat: NeuroSense Therapeutics Ltd lacks significant market leadership, network effects, or strong brand strength. The company operates in a competitive biotech sector with limited intellectual property and no significant cost advantages or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes NeuroSense Therapeutics might have No Moat - Very weak/transient advantages.

NeuroSense Therapeutics  (NAS:NRSNW) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

NeuroSense Therapeutics Moat Score Related Terms

NRSNW vs SNTI, LSTA, DYAI: Moat Score Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Moat Score falls into.


NRSNW
29GF Score
NeuroSense Therapeutics Ltd NRSNW
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
NeuroSense Therapeutics (NRSNW) has a Moat Score of 2 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, NeuroSense Therapeutics ranks #588 out of 1405 companies in the Biotechnology industry, placing it in the top 41.9%.
Is NeuroSense Therapeutics' Moat Score too high?
NeuroSense Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. NeuroSense Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, NeuroSense Therapeutics ranks #588 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Moat Score compare to SNTI and LSTA?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #588 out of 1405 companies for Moat Score. This puts NeuroSense Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. NeuroSense Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroSense Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroSense Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSNW) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSNW), the current Moat Score is 2 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges NRSN:USAH1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSNW

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price